363 related articles for article (PubMed ID: 23941127)
1. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
3. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
4. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
[TBL] [Abstract][Full Text] [Related]
5. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
[TBL] [Abstract][Full Text] [Related]
6. Evidence against PALB2 involvement in Icelandic breast cancer susceptibility.
Gunnarsson H; Arason A; Gillanders EM; Agnarsson BA; Johannesdottir G; Johannsson OT; Barkardottir RB
J Negat Results Biomed; 2008 Jul; 7():5. PubMed ID: 18637200
[TBL] [Abstract][Full Text] [Related]
7. Penetrance analysis of the PALB2 c.1592delT founder mutation.
Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
[TBL] [Abstract][Full Text] [Related]
8. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
9. A recurrent mutation in PALB2 in Finnish cancer families.
Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
[TBL] [Abstract][Full Text] [Related]
10. A PALB2 germline mutation associated with hereditary breast cancer in Italy.
Papi L; Putignano AL; Congregati C; Piaceri I; Zanna I; Sera F; Morrone D; Genuardi M; Palli D
Fam Cancer; 2010 Jun; 9(2):181-5. PubMed ID: 19763884
[TBL] [Abstract][Full Text] [Related]
11. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
13. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
14. PALB2 variants in hereditary and unselected Finnish prostate cancer cases.
Pakkanen S; Wahlfors T; Siltanen S; Patrikainen M; Matikainen MP; Tammela TL; Schleutker J
J Negat Results Biomed; 2009 Dec; 8():12. PubMed ID: 20003494
[TBL] [Abstract][Full Text] [Related]
15. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
[TBL] [Abstract][Full Text] [Related]
16. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
17. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
18. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
[TBL] [Abstract][Full Text] [Related]
19. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
